AU2002243730B2 - Subunit vaccines with A2 supermotifs - Google Patents

Subunit vaccines with A2 supermotifs Download PDF

Info

Publication number
AU2002243730B2
AU2002243730B2 AU2002243730A AU2002243730A AU2002243730B2 AU 2002243730 B2 AU2002243730 B2 AU 2002243730B2 AU 2002243730 A AU2002243730 A AU 2002243730A AU 2002243730 A AU2002243730 A AU 2002243730A AU 2002243730 B2 AU2002243730 B2 AU 2002243730B2
Authority
AU
Australia
Prior art keywords
peptide
antigen
peptides
amino acids
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002243730A
Other languages
English (en)
Other versions
AU2002243730A1 (en
Inventor
Howard M. Grey
Alessandro Sette
John Sidney
Scott Southwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmexa Inc
Original Assignee
Pharmexa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa Inc filed Critical Pharmexa Inc
Publication of AU2002243730A1 publication Critical patent/AU2002243730A1/en
Application granted granted Critical
Publication of AU2002243730B2 publication Critical patent/AU2002243730B2/en
Assigned to PHARMEXA INC. reassignment PHARMEXA INC. Request for Assignment Assignors: EPIMMUNE INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2002243730A 2001-01-29 2002-01-29 Subunit vaccines with A2 supermotifs Ceased AU2002243730B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26496901P 2001-01-29 2001-01-29
US60/264,969 2001-01-29
US09/935,476 US20040096445A1 (en) 1999-06-30 2001-08-22 Subunit vaccines with A2 supermotifs
US09/935,476 2001-08-22
PCT/US2002/002708 WO2002061435A2 (en) 2001-01-29 2002-01-29 Subunit vaccines with a2 supermotifs

Publications (2)

Publication Number Publication Date
AU2002243730A1 AU2002243730A1 (en) 2003-02-20
AU2002243730B2 true AU2002243730B2 (en) 2007-07-12

Family

ID=26950859

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002243730A Ceased AU2002243730B2 (en) 2001-01-29 2002-01-29 Subunit vaccines with A2 supermotifs

Country Status (14)

Country Link
US (1) US20040096445A1 (OSRAM)
EP (1) EP1368659A2 (OSRAM)
JP (1) JP2005512016A (OSRAM)
KR (1) KR20040052475A (OSRAM)
CN (1) CN1653337A (OSRAM)
AU (1) AU2002243730B2 (OSRAM)
CA (1) CA2432995C (OSRAM)
CZ (1) CZ20032054A3 (OSRAM)
IL (1) IL156660A0 (OSRAM)
MX (1) MXPA03006581A (OSRAM)
NZ (1) NZ526860A (OSRAM)
RU (1) RU2003126447A (OSRAM)
SK (1) SK9512003A3 (OSRAM)
WO (1) WO2002061435A2 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110097352A9 (en) * 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
WO2001021189A1 (en) * 1999-07-19 2001-03-29 Epimmune Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US20040248113A1 (en) * 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
WO2005012502A2 (en) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
EP3548897A4 (en) * 2016-12-01 2020-08-12 Nantomics, LLC PRESENTATION AND TREATMENT OF TUMOR ANTIGENICITY

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000225A1 (en) * 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
AU2605501A (en) * 1999-12-21 2001-07-03 Epimmune, Inc. Inducing cellular immune responses to prostate cancer antigens using peptide andnucleic acid compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000225A1 (en) * 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
AU2605501A (en) * 1999-12-21 2001-07-03 Epimmune, Inc. Inducing cellular immune responses to prostate cancer antigens using peptide andnucleic acid compositions

Also Published As

Publication number Publication date
US20040096445A1 (en) 2004-05-20
CA2432995A1 (en) 2002-08-08
CZ20032054A3 (cs) 2003-12-17
NZ526860A (en) 2007-03-30
RU2003126447A (ru) 2005-02-27
CA2432995C (en) 2011-07-26
WO2002061435A2 (en) 2002-08-08
SK9512003A3 (en) 2003-12-02
EP1368659A2 (en) 2003-12-10
CN1653337A (zh) 2005-08-10
KR20040052475A (ko) 2004-06-23
IL156660A0 (en) 2004-01-04
WO2002061435A3 (en) 2003-07-10
MXPA03006581A (es) 2004-06-25
JP2005512016A (ja) 2005-04-28

Similar Documents

Publication Publication Date Title
CN102066410B (zh) Hla‑dr结合肽和它们的应用
EP1917970B1 (en) Hla binding peptides and their uses
EP0914142B1 (en) Peptides with increased binding affinity for at least three hla-a3-like molecules
CA2248667C (en) Hla-a2.1 binding peptides and their uses
WO1997033602A9 (en) Peptides with increased binding affinity for hla molecules
EP1911461A2 (en) HLA class I and II binding peptides and their uses
AU2000232427A1 (en) HLA binding peptides and their uses
US20020177694A1 (en) Hla binding peptides and their uses
CA2432995C (en) Immunogenic hla-a2 supermotif-restricted peptides
AU2002243730A1 (en) Subunit vaccines with A2 supermotifs
US20040157273A1 (en) Subunit vaccines with a2 supermotifs
WO2002020616A1 (en) Hla-a2.1 binding peptides and their uses
EP1320377B1 (en) Hla binding peptides and their uses
EP1767542B1 (en) HLA-A2.1 binding peptides and their uses
AU4754899A (en) HLA Binding peptides and their uses

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: PHARMEXA INC.

Free format text: FORMER APPLICANT(S): EPIMMUNE INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired